AKR1C3 and liver cancer: The results indicated that there was no significant change in the expression of total AKT, when AKR1C3 was overexpressed in liver cancer cells (Figure 6B), while that of p-AKT was upregulated significantly in overexpressed AKR1C3 cells and in AKR1C3 overexpression cells with 10 μM sorafenib (Figure 6B).